Signatur Biosciences GTM brain

Signatur Biosciences is developing decentralized molecular prognostic tests for hospital and clinical laboratories, starting with breast cancer.

category

Breast cancer molecular diagnostics

market profile

  • text: Prognostic genomic testing can require centralized laboratories, international shipping and long waits for treatment decisions.
  • text: The first product is under development and is not available for sale, so clinical evidence and market authorization are central to adoption.

personas

  • title: Hospital molecular laboratory director
    pains:
    • Sending samples to reference labs adds turnaround time and cost.
    • New assays must fit existing equipment, staff capacity and quality processes.
  • title: Breast oncologist
    pains:
    • Waiting for genomic prognosis can delay treatment decisions.
    • Patients need accessible evidence to inform decisions about chemotherapy.
  • title: Hospital pathology procurement lead
    pains:
    • Specialist reference testing is expensive and access varies by geography.
    • Purchasing decisions depend on clinical validation, regulation and local reimbursement.

icp

  • text: Hospitals and clinical laboratories with standard qPCR equipment and breast oncology workloads are prospective adopters.
  • text: Health systems outside major reference centers, especially those shipping specimens abroad, face a stronger access and turnaround problem.

message pillars

  • text: Expand precision diagnostics beyond major centers.
  • text: Use existing local molecular testing equipment.
  • text: Reduce the wait for clinical insights.

objections

  • objection: Is the assay ready for clinical purchase?
    response: The company explicitly says its technology is in development and not for sale; ask for validation and regulatory milestones before procurement.
  • objection: Can a local lab trust the result against established genomic assays?
    response: Request head-to-head clinical validation, intended-use details and evidence of local workflow performance when available.

competitors

  • name: Exact Sciences
    why: Oncotype DX is an established breast cancer genomic testing alternative.
  • name: Myriad Genetics
    why: EndoPredict competes in breast cancer prognostic testing.
  • name: Agendia
    why: Offers breast cancer genomic testing in the same clinical decision market.

influencers

  • name: Celestin de Wergifosse
    url: https://www.linkedin.com/posts/celestin-de-wergifosse-41b9823b_proud-moment-for-signatur-biosciences-grateful-activity-7358824849458229248-oDPF
    why: Co-founder sharing progress on accessible breast cancer diagnostics.

keywords

  • breast cancer prognostic test
  • breast cancer genomic assay
  • local qPCR oncology testing
  • breast cancer recurrence risk test
  • Oncotype DX alternative
  • molecular diagnostics hospital lab

voice

  • mission-led and patient-centered
  • plain-language scientific
  • accessibility-focused

signals

  • text: A hospital is expanding molecular pathology or already operates qPCR equipment.
  • text: A breast cancer service reports long external genomic test turnaround times or access constraints.

stack

  • standard qPCR machines

hiring

  • Senior Technical Assistant, Liege, Belgium

pricing

model: unknown

motion

unknown

channels

  • LinkedIn
  • scientific conferences
  • press

confidence

medium

Founders

  • name: John Goertz
    title: Founder
    role: Founder
    bio: Co-founder, CSO, and PCRchitect at Signatur Biosciences. I teach machine learning to molecules to expand the range of diseases we can diagnose with PCR. NIH F32 Postdoctoral Fellow in the the Stevens Group at Imperial College London; PhD Bioengineering from University of Maryland, College Park; BSc Physics and Cell & Molecular Biology from Seattle University. When I’m not programming DNA, I’m cooking, running, or doing martial arts (Danzan-Ryu Japanese Jujitsu).
  • name: Celestin de Wergifosse
    title: Founder
    role: Founder
    bio: Co-founder and CEO of Signatur Biosciences. Startups since the age of 14. First patent at 15. WIPO Best Young Inventor 2010. Twice TEDx speaker. Co-founded Young Change Maker, a social startup that highlights inspiring individuals. Co-founded and sold a company called Sauna en Bois. Bio-engineering from Imperial College London. When I don't work, I race motorcycles, climb or ski. My life-long goal is to develop biotech companies that address global issues.

Back to YC companies